Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29222075 | 0.88 | MAPT (0.43) | USP2SMN1; SMN2NR1H2MAPTGRM5 | |
| SCHEMBL15846182 | 0.82 | USP2 (0.41) | USP2SMN1; SMN2NR1H2MTORMKNK1 | |
| SCHEMBL157874 | 0.80 | GRM5 (0.53) | GRM5 | |
| SCHEMBL175997 | 0.80 | USP2 (0.39) | USP2SMN1; SMN2NR1H2MTORDDB1 | |
| SCHEMBL15293389 | 0.80 | USP2 (0.39) | USP2SMN1; SMN2NR1H2MTORNAMPT | |
| SCHEMBL26090543 | 0.78 | USP2 (0.38) | USP2SMN1; SMN2NR1H2MTORMKNK1 | |
| SCHEMBL156126 | 0.77 | NR1H2 (0.41) | USP2SMN1; SMN2NR1H2MTORNAMPT | |
| SCHEMBL30889386 | 0.74 | CKS1B (0.45) | NAMPTGRM5GPR119C5AR1 | |
| SCHEMBL30785585 | 0.73 | MEN1 (0.44) | USP2MTORGRM5GPR119PIK3CA | |
| SCHEMBL158866 | 0.72 | GRM5 (0.44) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419525-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2025-07-17 | — | — | US | disclosed |
| EP-4419525-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| CN-118556059-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023067353-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| US-9090632-B2 | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090632-B2 | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090632-B2 | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors | VANDERBILT UNIVERSITY (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130261107-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261107-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261107-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2611298-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | Vanderbilt University (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012031024-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031024-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261107-A1 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS | GRM5, GRIK5, GRM1 | USP2 3637/4885SMN1; SMN2 1984/4885NR1H2 533/4885 |
| US-20250230165-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | NQO1, VHL, SDHA | USP2 4044/4885SMN1; SMN2 2654/4885NR1H2 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.